Trials / Completed
CompletedNCT00354809
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Morning Administration of GW679769 (10mg and 30 mg) on Polysomnograph Sleep Recordings, Subjective Sleep Assessment, Daytime Cognition and Psychomotor Function in Subjects With Primary Insomnia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9 days, will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with primary insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW679769 |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2006-07-20
- Last updated
- 2015-04-16
Locations
24 sites across 3 countries: United States, France, Germany
Source: ClinicalTrials.gov record NCT00354809. Inclusion in this directory is not an endorsement.